• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 - 2025
• Five Forces Analysis
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Product
o Market segments
o Comparison by Product
o Stimulants - Market size and forecast 2020-2025
o Non-stimulants - Market size and forecast 2020-2025
o Market opportunity by Product
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America - Market size and forecast 2020-2025
o Europe - Market size and forecast 2020-2025
o Asia - Market size and forecast 2020-2025
o ROW - Market size and forecast 2020-2025
o Key leading countries
o Market opportunity By Geographical Landscape
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Vendor Landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Aurobindo Pharma Ltd.
o Aytu BioPharma Inc.
o Eli Lilly and Co.
o Glenmark Pharmaceuticals Ltd.
o Johnson and Johnson Inc.
o Novartis AG
o Purdue Pharma LP
o SHIONOGI Co. Ltd.
o Takeda Pharmaceutical Co. Ltd.
o Tris Pharma Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global - Market size and forecast 2020 - 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 - 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition - Five forces 2020
• 21: Product - Market share 2020-2025 (%)
• 22: Comparison by Product
• 23: Stimulants - Market size and forecast 2020-2025 ($ million)
• 24: Stimulants - Year-over-year growth 2020-2025 (%)
• 25: Non-stimulants - Market size and forecast 2020-2025 ($ million)
• 26: Non-stimulants - Year-over-year growth 2020-2025 (%)
• 27: Market opportunity by Product
• 28: Customer landscape
• 29: Market share By Geographical Landscape 2020-2025 (%)
• 30: Geographic comparison
• 31: North America - Market size and forecast 2020-2025 ($ million)
• 32: North America - Year-over-year growth 2020-2025 (%)
• 33: Europe - Market size and forecast 2020-2025 ($ million)
• 34: Europe - Year-over-year growth 2020-2025 (%)
• 35: Asia - Market size and forecast 2020-2025 ($ million)
• 36: Asia - Year-over-year growth 2020-2025 (%)
• 37: ROW - Market size and forecast 2020-2025 ($ million)
• 38: ROW - Year-over-year growth 2020-2025 (%)
• 39: Key leading countries
• 40: Market opportunity By Geographical Landscape ($ million)
• 41: Impact of drivers and challenges
• 42: Vendor landscape
• 43: Landscape disruption
• 44: Industry risks
• 45: Vendors covered
• 46: Market positioning of vendors
• 47: Aurobindo Pharma Ltd. - Overview
• 48: Aurobindo Pharma Ltd. - Product and service
• 49: Aurobindo Pharma Ltd. - Key offerings
• 50: Aurobindo Pharma Ltd. - Key customers
• 51: Aurobindo Pharma Ltd. - Segment focus
• 52: Aytu BioPharma Inc. - Overview
• 53: Aytu BioPharma Inc. - Product and service
• 54: Aytu BioPharma Inc. - Key offerings
• 55: Aytu BioPharma Inc. - Key customers
• 56: Aytu BioPharma Inc. - Segment focus
• 57: Eli Lilly and Co. - Overview
• 58: Eli Lilly and Co. - Business segments
• 59: Eli Lilly and Co. - Key offerings
• 60: Eli Lilly and Co. - Key customers
• 61: Eli Lilly and Co. - Segment focus
• 62: Glenmark Pharmaceuticals Ltd. - Overview
• 63: Glenmark Pharmaceuticals Ltd. - Business segments
• 64: Glenmark Pharmaceuticals Ltd. - Key offerings
• 65: Glenmark Pharmaceuticals Ltd. - Key customers
• 66: Glenmark Pharmaceuticals Ltd. - Segment focus
• 67: Johnson and Johnson Inc. - Overview
• 68: Johnson and Johnson Inc. - Business segments
• 69: Johnson and Johnson Inc. - Key offerings
• 70: Johnson and Johnson Inc. - Key customers
• 71: Johnson and Johnson Inc. - Segment focus
• 72: Novartis AG - Overview
• 73: Novartis AG - Business segments
• 74: Novartis AG - Key offerings
• 75: Novartis AG - Key customers
• 76: Novartis AG - Segment focus
• 77: Purdue Pharma LP - Overview
• 78: Purdue Pharma LP - Product and service
• 79: Purdue Pharma LP - Key offerings
• 80: Purdue Pharma LP - Key customers
• 81: Purdue Pharma LP - Segment focus
• 82: SHIONOGI Co. Ltd. - Overview
• 83: SHIONOGI Co. Ltd. - Business segments
• 84: SHIONOGI Co. Ltd. - Key offerings
• 85: SHIONOGI Co. Ltd. - Key customers
• 86: SHIONOGI Co. Ltd. - Segment focus
• 87: Takeda Pharmaceutical Co. Ltd. - Overview
• 88: Takeda Pharmaceutical Co. Ltd. - Product and service
• 89: Takeda Pharmaceutical Co. Ltd. - Key offerings
• 90: Takeda Pharmaceutical Co. Ltd. - Key customers
• 91: Takeda Pharmaceutical Co. Ltd. - Segment focus
• 92: Tris Pharma Inc. - Overview
• 93: Tris Pharma Inc. - Product and service
• 94: Tris Pharma Inc. - Key offerings
• 95: Tris Pharma Inc. - Key customers
• 96: Tris Pharma Inc. - Segment focus
• 97: Currency conversion rates for US$
• 98: Research Methodology
• 99: Validation techniques employed for market sizing
• 100: Information sources
• 101: List of abbreviations

Companies Mentioned
. Aurobindo Pharma Ltd.
. Aytu BioPharma Inc.
. Eli Lilly and Co.
. Glenmark Pharmaceuticals Ltd.
. Johnson and Johnson Inc.
. Novartis AG
. Purdue Pharma LP
. SHIONOGI Co. Ltd.
. Takeda Pharmaceutical Co. Ltd.
. Tris Pharma Inc.